Amphotericin B is under clinical development by Matinas BioPharma and currently in Phase II for Pulmonary Cutaneous Zygomycosis (Mucormycosis). According to GlobalData, Phase II drugs for Pulmonary Cutaneous Zygomycosis (Mucormycosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Amphotericin B LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amphotericin B overview
Amphotericin B (MAT-2203) nanoparticle is under development for the treatment of mucocutaneous candidiasis, vulvovaginal candidiasis, pulmonary mucormycosis, cryptococcal meningitis, invasive candidiasis, aspergillosis, histoplasmosis, coccidioidomycosis and cryptococcosis. It is administered through oral route. The drug candidate is developed based on lipid nanocrystal (LNC) platform technology. Cochleates are multilayer crystalline, spiral structures with no internal aqueous space. It was also under development for the treatment of visceral leishmaniasis and hematological malignancy.
Matinas BioPharma overview
Matinas BioPharma is a biopharmaceutical company that discovers and develops anti-infectives for orphan indications. The company develops lipid nanocrystal (LNC) technology, a drug delivery platform to deliver various molecules such as small molecules, proteins, peptides, oligonucleotides, vaccines and gene editing technologies. Its pipeline products include MAT2203 and MAT2501, an LNC formulation of amikacin used for non-tuberculosis mycobacterium infections. The company partners with pharmaceutical and biotech companies to develop its LNC platform. Matinas BioPharma is headquartered in Bedminster, New Jersey, the US.
For a complete picture of Amphotericin B’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
